TY  - JOUR
AU  - Zeyen, Thomas
AU  - Paech, Daniel
AU  - Weller, Johannes
AU  - Schäfer, Niklas
AU  - Tzaridis, Theophilos
AU  - Duffy, Cathrina
AU  - Nitsch, Louisa
AU  - Schneider, Matthias
AU  - Potthoff, Anna-Laura
AU  - Steinbach, Joachim Peter
AU  - Hau, Peter
AU  - Schlegel, Uwe
AU  - Seidel, Clemens
AU  - Krex, Dietmar
AU  - Grauer, Oliver
AU  - Goldbrunner, Roland
AU  - Zeiner, Pia Susan
AU  - Tabatabai, Ghazaleh
AU  - Galldiks, Norbert
AU  - Stummer, Walter
AU  - Hattingen, Elke
AU  - Glas, Martin
AU  - Radbruch, Alexander
AU  - Herrlinger, Ulrich
AU  - Schaub, Christina
TI  - Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
JO  - Journal of neuro-oncology
VL  - 164
IS  - 3
SN  - 0167-594X
CY  - Dordrecht [u.a.]
PB  - Springer Science + Business Media B.V
M1  - FZJ-2023-04876
SP  - 607 - 616
PY  - 2023
N1  - Erratum in Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. Zeyen T, Paech D, Weller J, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Steinbach JP, Hau P, Schlegel U, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Radbruch A, Herrlinger U, Schaub C. J Neurooncol. 2023 Nov 3. doi: 10.1007/s11060-023-04488-z. 
AB  - Purpose: In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma. Progression-free survival (PFS) and pseudoprogression rates (about 10%) were similar in both arms. Further evaluating this discrepancy, we analyzed patterns of postprogression survival (PPS) and MRI features at first progression according to modified RANO criteria (mRANO).Methods: We classified the patients of the CeTeG/NOA-09 trial according to long vs. short PPS employing a cut-off of 18 months and compared baseline characteristics and survival times. In patients with available MRIs and confirmed progression, the increase in T1-enhancing, FLAIR hyperintense lesion volume and the change in ADC mean value of contrast-enhancing tumor upon progression were determined.Results: Patients with long PPS in the CCNU/TMZ arm had a particularly short PFS (5.6 months). PFS in this subgroup was shorter than in the long PPS subgroup of the TMZ arm (11.1 months, p = 0.01). At mRANO-defined progression, patients of the CCNU/TMZ long PPS subgroup had a significantly higher increase of mean ADC values (p = 0.015) and a tendency to a stronger volumetric increase in T1-enhancement (p = 0.22) as compared to long PPS patients of the TMZ arm.Conclusion: The combination of survival and MRI analyses identified a subgroup of CCNU/TMZ-treated patients with features that sets them apart from other patients in the trial: short first PFS despite long PPS and significant increase in mean ADC values upon mRANO-defined progression. The observed pattern is compatible with the features commonly observed in pseudoprogression suggesting mRANO-undetected pseudoprogressions in the CCNU/TMZ arm of CeTeG/NOA-09.Keywords: Glioblastoma; MGMT promotor methylation; MRI; Progression; Pseudoprogression.
LB  - PUB:(DE-HGF)16
C6  - 37728779
UR  - <Go to ISI:>//WOS:001068390300001
DO  - DOI:10.1007/s11060-023-04444-x
UR  - https://juser.fz-juelich.de/record/1018548
ER  -